Clinical outcomes reveal high healthcare burden in triple-class exposed multiple myeloma patients, suggesting a need for novel therapies.
Treatment for TCE patients has limited effectiveness and a high healthcare system burden, emphasizing the unmet need for therapies with novel mechanisms of action.
No takes yet. Share an insight, caveat, or question.
Jimenez-Zepeda et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: